Pharmaceutical excipients are inactive substances in the drug which helps in modulating solubility, bioavailability, and stability of active substances for formulating final drug dosage forms. The excipients form the major part in any medicinal product and proportion of it when compared to Active Pharmaceutical Ingredient (API) exceeds two to three folds in any pharmaceutical preparations. Hence, various characteristics such as functionality, regulatory status, sources, cost, consistency, bioavailability, physicochemical properties, stability, and pharmacokinetic parameters, etc. play a major role in determining the suitability of a substance as an excipient.
As estimated by IQ4I Research, the pharmaceutical excipients global market is expected to grow at a single digit CAGR from 2018 to 2025 to reach $9,911.2 million by 2025. The pharmaceutical excipients market is segmented by source, products, process, functionality, drug dosage forms and finished products.
Pharmaceutical excipients market by the source is segmented as animal-based, plant-based, mineral-based and synthetic based excipients. Plant-based excipients held the highest revenue in 2018 and it is a fastest growing segment at a high single digit CAGR from 2018 to 2025, due to plant-based excipients are cost-effective, low toxic with the better patient tolerance, bio-compatible and they are easily available. By-products, excipients are segmented into inorganic chemicals, organic chemicals and pharmaceutical water. The organic chemicals segment held the highest revenue in 2018 and it is expected to grow at a single digit CAGR from 2018 to 2025, due to the use of these excipients in majorly all of the pharmaceutical formulations as they offer advantages such as increased efficacy in oral delivery of poorly soluble molecules along with increased compressibility and flowability properties.
Inorganic chemical excipients market by type, are further divided into calcium salts, halites, metallic oxides, silicates, and other inorganic chemicals, among which metallic oxides held a major revenue in 2018 and Calcium salts segment is expected to grow at a high single digit CAGR from 2018 to 2025. Calcium salts are further sub-segmented into calcium phosphate and calcium carbonate, among which calcium phosphate held the highest revenue in 2018 and calcium carbonate segment is expected to grow at a high single digit CAGR from 2018 to 2025. Calcium carbonate is further classified into GCC and PCC, among which PCC held the highest revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025. Metallic oxides segment are further segmented into titanium dioxide and Others (Iron Oxide, Magnesium Oxide & Aluminum Hydroxide). Titanium Dioxide held the highest revenue in 2018 and it is expected to grow at a mid single digit CAGR from 2018 to 2025.
Organic chemical excipients market by type is further divided into carbohydrates, petrochemicals, oleochemicals, proteins, and other organic chemicals. Oleochemicals held major revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025.
Carbohydrate excipients market by type is further segmented into sugar, starch, and cellulose, among which sugar held the largest revenue in 2018 and expected to grow at a mid single digit CAGR from 2018 to 2025. Sugar segment is further divided into actual sugar, sugar alcohol, and artificial sweeteners, where actual sugar held the largest revenue in 2018 and sugar alcohol segment is expected to grow at a mid single digit CAGR from 2018 to 2025.
Actual sugar segment is further sub-segmented into lactose, sucrose, and dextrose, where lactose held the largest revenue in 2018 and dextrose segment is expected to grow at a mid single digit CAGR from 2018 to 2025. Sugar alcohol segment is further classified into sorbitol, mannitol and other sugar alcohols, where mannitol held the largest revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025. The starch segment is further divided into modified starch, dried starch and converted starch, where modified starch held the largest revenue in 2018 and dried starch is expected to grow at a mid single digit CAGR from 2018 to 2025. Cellulose segment is further sub-segmented into cellulose ethers, cellulose esters, croscarmellose sodium, and microcrystalline cellulose, where cellulose ethers held the largest revenue in 2018 and microcrystalline cellulose is expected to grow at a mid single digit CAGR from 2018 to 2025.
Petrochemical excipients market by type is further segmented into glycols, povidones, mineral hydrocarbons, acrylic polymers, and other petrochemical excipients. Glycol held the largest revenue in 2018 and acrylic polymers is expected to grow at a high single digit CAGR from 2018 to 2025. Glycol segment is further segmented into Polyethylene Glycol and Propylene Glycol, where Polyethylene Glycol held the largest revenue in 2018 it is expected to grow at a mid single digit CAGR from 2018 to 2025.
Oleochemicals excipients market by type is further segmented into Fatty Alcohols, Metal stearates, Glycerin, and Other Oleochemical Excipients. Fatty Alcohol held the largest revenue in 2018 and Metal stearates is expected to grow at a high single digit CAGR from 2018 to 2025.
Pharma/USP water excipients market by type is further segment into the water for injections and purified water. Water for injections held the largest revenue in 2018 and it is expected to grow at a mid single digit CAGR from 2018 to 2025. Pharmaceutical excipients market by the process is segmented as granulation and direct compression. Granulation held the largest revenue in 2018 and direct compression is expected to grow at a high single digit CAGR from 2018 to 2025.
Pharmaceutical excipients market by functionality is segmented as preservatives, solvent, binders & adhesives, fillers & diluents, suspending agent, coatings, solubilizer, disintegrant, colorant, flavoring & sweeteners, lubricants & glidants, and others. Binders & Adhesives held the largest revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025.
Pharmaceutical excipients market by dosage forms is segmented as solid dosage forms, injectables and semisolid, liquid and gaseous. Solid dosage forms held the largest revenue in 2018 and it is expected to grow at a high single digit CAGR from 2018 to 2025. Some of the factors driving the market are solid dosage forms are cost-effective, solid dosage provides increased physical and chemical stability, controlled-release options, and superior ease of handling.
Pharmaceutical excipients market by finished products is segmented as Prescription drugs and OTC. Prescription drugs held the largest revenue in 2018 and it is expected to grow at a mid single digit CAGR from 2018 to 2025.
Pharmaceutical excipients market by region is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others) and Rest of the world (Brazil, Rest of Latin America and Middle East & others). North America held the highest revenue in 2018, due to increasing demand for functional excipients, implementation of new novelties like nanotechnology, increasing usage of oral solid dosage forms, increasing incidence of chronic disorders, elderly population and favorable reimbursement scenario for drugs. Asia-Pacific is the fastest growing region with a high single digit CAGR from 2018 to 2025, due to increasing excipients outsourcing by companies, low manufacturing, and low labor costs, adopting modern innovations like nanotechnology, advancement in the development of functional excipients, rise in chronic diseases, growing generics market owing to patent cliffs, rising healthcare demand, better infrastructure, lower capital, and overhead costs. Excipients manufacturers in developing countries face major challenges to develop product with quality at an affordable price, due to lower price of excipients and large number of producers, which creates a price sensitive market. Some manufacturers may compromise the quality of product in order to keep prices low and boost sales, while some of the manufacturers having a larger market for their products, can sell their higher volume excipients at a slightly lower price.
Some of the key players contributing at global level for pharmaceutical excipients market growth are Dow DuPont (U.S.), Ashland, Inc. (U.S.), BASF SE (Germany), DFE Pharma (Germany), Evonik Industries AG (Germany), Associated British Foods Plc (U.K.), Merck KGAA (U.S.), Roquette (France), Colorcon (U.S.), and Asahi Kasei (Japan).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
鈥� North America
o U.S.
o Rest of North America
鈥� Europe
o Germany
o France
o Italy
o Rest of Europe
鈥� Asia-Pacific
o China
o India
o Japan
o Rest of APAC
鈥� Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle East and Others
1 EXECUTIVE SUMMARY 34
2 INTRODUCTION 41
2.1 KEY TAKEAWAYS 41
2.2 SCOPE OF THE REPORT 42
2.3 REPORT DESCRIPTION 42
2.4 MARKETS COVERED 47
2.5 STAKEHOLDERS 49
2.6 RESEARCH METHODOLOGY 49
2.6.1 MARKET SIZE ESTIMATION 51
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 53
2.6.3 SECONDARY SOURCES 54
2.6.4 KEY DATA POINTS FROM SECONDARY SOURCES 55
2.6.5 PRIMARY SOURCES 56
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 57
2.6.7 ASSUMPTIONS 57
3 MARKET ANALYSIS 59
3.1 INTRODUCTION 59
3.2 MARKET SEGMENTATION 60
3.3 FACTORS INFLUENCING MARKET 62
3.3.1 DRIVERS AND OPPORTUNITIES 63
3.3.1.1 Growth in generics and biosimilar drugs 63
3.3.1.2 Increasing demand for OSDF excipients 63
3.3.1.3 Increasing demand for multifunctional excipients 64
3.3.1.4 Drug-coated medical devices 65
3.3.1.5 Increased demand for solubility enhancing excipients 66
3.3.1.6 Rising demand for sustained or controlled release formulations 67
3.3.1.7 Novel excipients for biologic drugs 67
3.3.1.8 Increasing prevalence of chronic diseases, rise in the aging population 68
3.3.2 RESTRAINTS AND THREATS 69
3.3.2.1 Adverse reactions of excipients 69
3.3.2.2 Contamination in formulations 70
3.3.2.3 High market fragmentation with low-profit margins 71
3.3.2.4 Demand for safe and quality excipients by regulatory authorities 71
3.4 REGULATORY AFFAIRS 72
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 72
3.4.1.1 ISO 9001: 2015 quality management system 72
3.4.2 INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL (IPEC FEDERATION) 73
3.4.3 PHARMACEUTICAL QUALITY GROUP (PQG) 73
3.4.4 U.S. 73
3.4.5 EUROPE 75
3.4.6 JAPAN 75
3.4.7 CHINA 76
3.4.8 INDIA 76
3.4.9 REST OF THE WORLD 77
3.5 PORTER鈥橲 FIVE FORCE ANALYSIS 78
3.5.1 THREAT OF NEW ENTRANTS 79
3.5.2 THREAT OF SUBSTITUTES 79
3.5.3 BARGAINING POWER OF SUPPLIERS 80
3.5.4 BARGAINING POWER OF BUYERS 80
3.5.5 COMPETITIVE RIVALRY 81
3.6 SUPPLY CHAIN ANALYSIS 82
3.7 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 85
3.7.1 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE ANALYSIS 85
3.8 NOVEL EXCIPIENTS 89
3.9 MOLECULE TYPE 90
3.10 DRUG MASTER FILING (DMF) 94
3.11 EXCIPIENTS BY MOLECULE TYPE 95
3.12 EXCIPIENTS PRICING 96
3.13 GLOBAL PHARMACEUTICAL EXCIPIENTS PRODUCTION VOLUME 99
3.14 EXCIPIENTS USED IN GLOBAL TOP 100 SELLING DRUGS BY REVENUE 101
3.15 EXCIPIENT MANUFACTURER鈥橲 REVENUE, PRODUCT, FUNCTIONALITY AND DOSAGE FORMS 148
4 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY SOURCE 156
4.1 INTRODUCTION 156
4.2 ANIMAL BASED EXCIPIENTS 159
4.3 PLANT BASED EXCIPIENTS 162
4.4 MINERAL BASED EXCIPIENTS 165
4.5 SYNTHETIC BASED EXCIPIENTS 168
5 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY PRODUCT 171
5.1 INTRODUCTION 171
5.2 INORGANIC CHEMICALS 175
5.2.1 CALCIUM SALTS 181
5.2.1.1 Calcium phosphate 186
5.2.1.2 Calcium carbonate 188
5.2.1.2.1 GCC 192
5.2.1.2.2 PCC 194
5.2.1.3 OTHER CALCIUM SALT 196
5.2.2 HALITES 198
5.2.3 METALLIC OXIDES 201
5.2.3.1 Titanium dioxide 206
5.2.3.2 Other metallic oxides 207
5.2.4 SILICATES 209
5.2.5 OTHER INORGANIC CHEMICALS 213
5.3 ORGANIC CHEMICALS 216
5.3.1 CARBOHYDRATES 222
5.3.1.1 Sugar 228
5.3.1.1.1 Actual sugar 231
5.3.1.1.1.1 Lactose 234
5.3.1.1.1.2 Sucrose 236
5.3.1.1.1.3 Dextrose 238
5.3.1.1.2 Sugar alcohol 240
5.3.1.1.2.1 Sorbitol 243
5.3.1.1.2.2 Mannitol 245
5.3.1.1.2.3 Other sugar alcohols 247
5.3.1.1.3 Artificial sweeteners 249
5.3.1.2 Starch 251
5.3.1.2.1 Modified starch 255
5.3.1.2.2 Dried starch 258
5.3.1.2.3 Converted starch 259
5.3.1.3 Cellulose 261
5.3.1.3.1 Cellulose ethers 265
5.3.1.3.2 Cellulose esters 267
5.3.1.3.3 Croscarmellose sodium 269
5.3.1.3.4 Microcrystalline cellulose 271
5.3.2 PETROCHEMICALS 273
5.3.2.1 Glycol 278
5.3.2.1.1 Polyethylene glycol 280
5.3.2.1.2 Propylene glycol 282
5.3.2.2 Povidones 284
5.3.2.3 Mineral hydrocarbons 286
5.3.2.3.1 Petrolatum 287
5.3.2.3.2 Mineral waxes 287
5.3.2.3.3 Mineral oils 287
5.3.2.4 Acrylic polymers 288
5.3.2.5 Other petrochemicals 290
5.3.3 OLEOCHEMICALS 292
5.3.3.1 Fatty alcohols 297
5.3.3.2 Metal stearates 299
5.3.3.3 Glycerin 301
5.3.3.4 Other oleochemicals 303
5.3.4 PROTEINS 305
5.3.5 OTHER ORGANIC CHEMICALS 308
5.4 PHARMA/USP WATER 311
5.4.1 WATER FOR INJECTION 316
5.4.2 PURIFIED WATER 319
6 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY MANUFACTURING PROCESS 322
6.1 INTRODUCTION 322
6.2 GRANULATION 325
6.3 DIRECT COMPRESSION 328
7 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY FUNCTIONALITY 331
7.1 INTRODUCTION 331
7.2 PRESERVATIVES 334
7.3 SOLVENT 337
7.4 BINDERS & ADHESIVES 339
7.5 FILLERS & DILUENTS 342
7.6 SUSPENDING AGENT 345
7.7 COATINGS 348
7.8 SOLUBILIZERS 351
7.9 DISINTEGRANT 354
7.10 COLORANT, FLAVOURING & SWEETENERS 357
7.11 LUBRICANTS & GLIDANTS 360
7.12 OTHERS 363
8 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY DOSAGE FORMS 368
8.1 INTRODUCTION 368
8.2 SOLID DOSAGE FORMS 371
8.3 INJECTABLES 374
8.4 SEMISOLID, LIQUID AND GASEOUS 377
9 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BY FINISHED PRODUCTS 380
9.1 INTRODUCTION 380
9.2 PRESCRIPTION DRUGS 383
9.3 OVER-THE-COUNTER (OTC) DRUGS 386
10 REGIONAL ANALYSIS 389
10.1 INTRODUCTION 389
10.2 NORTH AMERICA 394
10.2.1 U.S. 422
10.2.2 REST OF NORTH AMERICA 428
10.3 EUROPE 433
10.3.1 GERMANY 460
10.3.2 FRANCE 464
10.3.3 ITALY 468
10.3.4 REST OF EUROPE 472
10.4 APAC 476
10.4.1 CHINA 503
10.4.2 INDIA 507
10.4.3 JAPAN 512
10.4.4 REST OF APAC 516
10.5 ROW 520
10.5.1 BRAZIL 547
10.5.2 REST OF LATAM 550
10.5.3 MIDDLE EAST & OTHERS 553
11 COMPETITIVE LANDSCAPE 557
11.1 INTRODUCTION 557
11.2 NEW PRODUCT LAUNCHES 558
11.3 ACQUISITION 561
11.4 AGREEMENTS, COLLABORATION & JOINT VENTURES 562
12 MAJOR COMPANIES 565
12.1 ASAHI KASEI 565
12.1.1 OVERVIEW 565
12.1.2 FINANCIALS 566
12.1.3 PRODUCT PORTFOLIO 569
12.1.4 KEY DEVELOPMENTS 569
12.1.5 BUSINESS STRATEGY 569
12.1.6 SWOT ANALYSIS 570
12.2 ASHLAND, INC 571
12.2.1 OVERVIEW 571
12.2.2 FINANCIALS 572
12.2.3 PRODUCT PORTFOLIO 575
12.2.4 KEY DEVELOPMENTS 577
12.2.5 BUSINESS STRATEGY 578
12.2.6 SWOT ANALYSIS 579
12.3 ASSOCIATED BRITISH FOODS PLC (SPI PHARMA) 580
12.3.1 OVERVIEW 580
12.3.2 FINANCIALS 581
12.3.3 PRODUCT PORTFOLIO 584
12.3.4 KEY DEVELOPMENTS 585
12.3.5 BUSINESS STRATEGY 585
12.3.6 SWOT ANALYSIS 586
12.4 AVANTOR INC 587
12.4.1 OVERVIEW 587
12.4.2 FINANCIALS 587
12.4.3 PRODUCT PORTFOLIO 588
12.4.4 KEY DEVELOPMENTS 588
12.4.5 BUSINESS STRATEGY 589
12.4.6 SWOT ANALYSIS 590
12.5 BASF SE 591
12.5.1 OVERVIEW 591
12.5.2 FINANCIALS 592
12.5.3 PRODUCT PORTFOLIO 595
12.5.4 KEY DEVELOPMENTS 596
12.5.5 BUSINESS STRATEGY 597
12.5.6 SWOT ANALYSIS 598
12.6 COLORCON, INC. 599
12.6.1 OVERVIEW 599
12.6.2 FINANCIALS 599
12.6.3 PRODUCT PORTFOLIO 600
12.6.4 KEY DEVELOPMENTS 600
12.6.5 BUSINESS STRATEGY 601
12.6.6 SWOT ANALYSIS 602
12.7 CRODA INTERNATIONAL PLC 603
12.7.1 OVERVIEW 603
12.7.2 FINANCIALS 604
12.7.3 PRODUCT PORTFOLIO 607
12.7.4 KEY DEVELOPMENTS 607
12.7.5 BUSINESS STRATEGY 609
12.7.6 SWOT ANALYSIS 610
12.8 DFE PHARMA 611
12.8.1 OVERVIEW 611
12.8.2 FINANCIALS 611
12.8.3 PRODUCT PORTFOLIO 612
12.8.4 KEY DEVELOPMENTS 613
12.8.5 BUSINESS STRATEGY 614
12.8.6 SWOT ANALYSIS 615
12.9 DOW DUPONT INC. 616
12.9.1 OVERVIEW 616
12.9.2 FINANCIALS 617
12.9.3 PRODUCT PORTFOLIO 620
12.9.4 KEY DEVELOPMENTS 621
12.9.5 BUSINESS STRATEGY 621
12.9.6 SWOT ANALYSIS 622
12.10 EVONIK INDUSTRIES AG 623
12.10.1 OVERVIEW 623
12.10.2 FINANCIALS 624
12.10.3 PRODUCT PORTFOLIO 627
12.10.4 KEY DEVELOPMENTS 627
12.10.5 BUSINESS STRATEGY 628
12.10.6 SWOT ANALYSIS 629
12.11 LUBRIZOL CORPORATION 630
12.11.1 OVERVIEW 630
12.11.2 FINANCIALS 630
12.11.3 PRODUCT PORTFOLIO 631
12.11.4 KEY DEVELOPMENTS 632
12.11.5 BUSINESS STRATEGY 633
12.11.6 SWOT ANALYSIS 634
12.12 MERCK KGAA 635
12.12.1 OVERVIEW 635
12.12.2 FINANCIALS 636
12.12.3 PRODUCT PORTFOLIO 639
12.12.4 KEY DEVELOPMENTS 640
12.12.5 BUSINESS STRATEGY 641
12.12.6 SWOT ANALYSIS 642
12.13 ROQUETTE FR脠RES S.A. 643
12.13.1 OVERVIEW 643
12.13.2 FINANCIALS 643
12.13.3 PRODUCT PORTFOLIO 644
12.13.4 KEY DEVELOPMENTS 645
12.13.5 BUSINESS STRATEGY 646
12.13.6 SWOT ANALYSIS 647
ASAHI KASEI
ASHLAND INC.
ASSOCIATED BRITISH FOODS PLC (SPI PHARMA)
AVANTOR PERFORMANCE MATERIALS
BASF SE
COLORCON, INC.
CRODA INTERNATIONAL PLC
DFE PHARMA
DOW DUPONT INC.
EVONIK INDUSTRIES AG
LUBRIZOL CORPORATION
MERCK KGAA
ROQUETTE
LIST OF COMPANIES MENTIONED IN THE REPORT
A & C AMERICAN CHEMICALS LIMITED
ACCENT MICROCELL PRIVATE LIMITED
ACG ASSOCIATED CAPSULES PRIVATE LIMITED
AKHIL HEALTHCARE PVT. LTD.
ANHUI SUNHERE PHARMACEUTICAL EXCIPIENTS CO., LTD.
ARCHER DANIELS MIDLAND COMPANY
ARMOR PHARMA
ASAHI KASEI CORPORATION
ASHA CELLULOSE (I) PVT. LTD.
ASHLAND INC.
ASSOCIATED BRITISH FOODS PLC
AUG. HEDINGER GMBH & CO. KG
AVANTOR, INC.
BASF SE
BENEO
BIOGRUND GMBH
BRENNTAG AG
CARGILL, INCORPORATED
CELANESE CORPORATION
CHEMFIELD CELLULOSE PVT. LTD.
CHEMPILOTS A/S
COLORCON INC.
CORDENPHARMA INTERNATIONAL
COREL PHARMA CHEM
CREST CELLULOSE PVT. LTD.
CRODA INTERNATIONAL PLC
DAFFODIL PHARMA
DFE PHARMA
DOW DUPONT INC.
EASTMAN CHEMICAL COMPANY
EVONIK INDUSTRIES AG
FINAR LIMITED
GANGWAL CHEMICALS PRIVATE LIMITED
GATTEFOSS脡 SAS
HENGYANG DESEN BIOTECHNOLOGY CO., LTD.
HUZHOU ZHANWANG PHARMACEUTICAL CO., LTD.
IDEAL CURES PVT. LTD.
IMPAG GROUP
INGREDION INCORPORATED
JAYSONS API PRIVATE LIMITED
JD PHARMASCIENCES
JRS PHARMA
KASYAP SWEETNERS LIMITED
KERRY GROUP
LACTOSE INDIA LTD.
LIAONING OXIRANPHEX INC.
LUBRIZOL CORPORATION
MAPLE BIOTECH PRIVATE LIMITED
MEGGLE PHARMA
MERCK MILLIPORE
MINERAL TECHNOLOGIES INC.
NITIKA PHARMACEUTICALS SPECIALITIES PVT. LTD.
OMYA INTERNATIONAL AG
PATEL CHEM SPECIALITIES PRIVATE LIMITED
PAUSHAK LIMITED
PFANSTIEHL INC.
RELIANCE CELLULOSE PRODUCTS LIMITED
ROQUETTE FR脠RES SA
SAUDI KAYAN PETROCHEMICAL COMPANY (SABIC)
SAVVY SPECHEMS PRIVATE LIMITED
SELECT CHEMIE AG
SEPPIC SA
SEQENS SAS
SHREEJI PHARMA INTERNATIONAL
SIGACHI INDUSTRIES PRIVATE LIMITED
SIGNET CHEMICAL CORPORATION PRIVATE LIMITED
SNA HEALTHCARE PRIVATE LIMITED
SOLVAY SA
SPECTRUM CHEMICAL MANUFACTURING CORP.
STROEVER GMBH & CO. KG
SUDEEP PHARMA PVT. LTD.
SURFACHEM GROUP LTD.
TEREOS SA
VALTRIS SPECIALTY CHEMICAL
VENATOR MATERIALS PLC
VIKAASH CHEMICALS
VIKRAM THERMO LTD.
WACKER CHEMIE AG
W. R. GRACE & CO.-CONN.
XIAMEN SHENGLANG SAICHUANG BIOLOGICAL TECHNOLOGY CO.
ZUCHEM INC.
听
听
*If Applicable.
